Susan Raju Paul, M.B.,B.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Coxiella burnetii | 6 | 2023 | 37 | 2.460 |
Why?
|
| Q Fever | 6 | 2023 | 37 | 2.440 |
Why?
|
| Epitopes, T-Lymphocyte | 3 | 2022 | 880 | 0.300 |
Why?
|
| Bacterial Vaccines | 4 | 2022 | 403 | 0.270 |
Why?
|
| Interleukin-2 | 2 | 2023 | 1904 | 0.270 |
Why?
|
| Interleukin-6 | 2 | 2023 | 3201 | 0.220 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2023 | 4419 | 0.200 |
Why?
|
| Chemokine CXCL10 | 1 | 2022 | 304 | 0.200 |
Why?
|
| Immunity, Innate | 2 | 2023 | 2958 | 0.180 |
Why?
|
| Cytokines | 3 | 2023 | 7326 | 0.170 |
Why?
|
| Australia | 1 | 2022 | 1169 | 0.170 |
Why?
|
| Antibodies, Bacterial | 2 | 2022 | 1470 | 0.150 |
Why?
|
| Immunophenotyping | 1 | 2021 | 1880 | 0.140 |
Why?
|
| Immunity, Cellular | 1 | 2020 | 1607 | 0.120 |
Why?
|
| Antigens, Bacterial | 1 | 2019 | 1171 | 0.120 |
Why?
|
| Immunologic Memory | 1 | 2019 | 1348 | 0.100 |
Why?
|
| Vaccination | 1 | 2022 | 3278 | 0.090 |
Why?
|
| Enzyme-Linked Immunospot Assay | 2 | 2019 | 130 | 0.080 |
Why?
|
| Guinea Pigs | 2 | 2022 | 1386 | 0.080 |
Why?
|
| T-Lymphocytes | 3 | 2022 | 10182 | 0.080 |
Why?
|
| Wounds and Injuries | 1 | 2021 | 2400 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 1971 | 0.080 |
Why?
|
| Kidney Transplantation | 1 | 2023 | 4251 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 4385 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2023 | 5442 | 0.060 |
Why?
|
| Genes, bcl-2 | 1 | 2023 | 122 | 0.060 |
Why?
|
| Chimerism | 1 | 2023 | 158 | 0.050 |
Why?
|
| Interferon-gamma | 2 | 2019 | 3203 | 0.050 |
Why?
|
| Primates | 1 | 2023 | 544 | 0.050 |
Why?
|
| Convalescence | 1 | 2019 | 105 | 0.040 |
Why?
|
| HLA-DR Antigens | 1 | 2020 | 645 | 0.040 |
Why?
|
| Peptides | 2 | 2022 | 4407 | 0.040 |
Why?
|
| Injury Severity Score | 1 | 2021 | 1013 | 0.040 |
Why?
|
| Transplantation Tolerance | 1 | 2023 | 617 | 0.040 |
Why?
|
| Histocompatibility Testing | 1 | 2019 | 742 | 0.040 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2019 | 1475 | 0.030 |
Why?
|
| Humans | 7 | 2023 | 744220 | 0.030 |
Why?
|
| Immunization | 1 | 2019 | 1256 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2022 | 77426 | 0.030 |
Why?
|
| HLA Antigens | 1 | 2019 | 1382 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2019 | 1366 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 2133 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 6386 | 0.020 |
Why?
|
| Monocytes | 1 | 2020 | 2594 | 0.020 |
Why?
|
| Animals | 4 | 2023 | 168788 | 0.020 |
Why?
|
| Critical Illness | 1 | 2021 | 2670 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2020 | 9735 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2021 | 3680 | 0.020 |
Why?
|
| Length of Stay | 1 | 2021 | 6308 | 0.020 |
Why?
|
| Gene Expression | 1 | 2019 | 7799 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2019 | 9147 | 0.020 |
Why?
|
| Mice | 2 | 2022 | 81178 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2022 | 21824 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2021 | 21752 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 18027 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 7179 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2021 | 23337 | 0.010 |
Why?
|
| Female | 3 | 2021 | 380197 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2021 | 53280 | 0.010 |
Why?
|
| Middle Aged | 2 | 2021 | 213367 | 0.010 |
Why?
|
| Male | 2 | 2021 | 350027 | 0.010 |
Why?
|
| Aged | 1 | 2019 | 163253 | 0.000 |
Why?
|
| Adult | 1 | 2021 | 214035 | 0.000 |
Why?
|